The Biostatistics Core will have a collaborative role in the statistical design, the statistical analysis, and the dissemination of research results for all experimental and clinical studies defined in the project proposals and studies, proposed and awarded, from the Career Development and Research Development Programs for this SPORE on Skin Cancer. The members of this core include three senior biostatisticians who have strong existing collaborations with SPORE investigators, relevant knowledge of biostatistical methods and their application to research proposed in the SPORE, and an extensive publication record that reflect their expertise and collaborations in skin cancer. The Biostatistics Core will provide expertise and experience in three areas. The first is research methodology for study design including population definition, measurement issues, potential bias, sample size and power, randomization and efficient experimental design. The second is statistical methodology for estimation, hypothesis testing and modeling as well as for conducting methodological research to solve practical problems that arise, comparing alternative methodologies and conducting discovery studies that are motivated by for the translational goals of the SPORE research projects. The third area is interpretation and presentation of research data that are supported by scientifically and statistically justified statements for dissemination of knowledge gained from research studies. The Biostatistics Core personnel have established collaborations through one-on-one meetings and project meetings with SPORE investigators. These collaborations have led to 29 publications (2007-2012) that have contributed significantly to our understanding of melanoma.

Public Health Relevance

Collaboration between the senior biostatisticians in the Biostatistics Core and the research investigators conducting SPORE-related studies will insure that the SPORE research studies will have high quality study designs and relevant statistical analysis plans that will provide a solid foundation for each study's conclusions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4
Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24
Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30
Fatkhutdinov, Nail; Sproesser, Katrin; Krepler, Clemens et al. (2016) Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res 14:767-75
Kumar, Vinit; Cheng, Pingyan; Condamine, Thomas et al. (2016) CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity 44:303-15
Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res 29:317-28
Gimotty, Phyllis A; Shore, Ronald; Lozon, Nancy L et al. (2016) Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. J Invest Dermatol 136:2168-2172
Natale, Christopher A; Duperret, Elizabeth K; Zhang, Junqian et al. (2016) Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors. Elife 5:
Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602
Wang, Joshua X; Fukunaga-Kalabis, Mizuho; Herlyn, Meenhard (2016) Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. J Cell Commun Signal 10:191-196

Showing the most recent 10 out of 35 publications